patient population it sort of came to me today when I was looking at the characteristics of
the patient population that was in this study average age, and correct me if I am wrong on
any of this, the average age was about early 50s and with a relatively recent onset of type
2 diabetes. As John Teerlink pointed out, the cardiovascular risks are much more
pronounced in populations that are 65 and older and have had diabetes for ten years or
more, certainly longer than the peak patients in this population had, in the study.
view and take a sort of a 30,000-foot look at this. When I looked at question number one
I really thought that it sort of got to the heart of the matter, no pun intended with that.
Because, for me, it was one of relevance and when I was trying to dissect this and get
away from torturing myself with very daunting statistics, I started looking at this low
event rate and said, so what does that mean?
assessment most relevant and it’s for those older patients, it’s for those ones who have
these events who were not represented highly in this particular study. So, you know,
going back to prior concerns that I voiced, I look at this idea of setting a cardiovascular
risk hurdle for new drugs may place a burden on those diabetics who don’t fit into those
parameters; the ones who develop type 2 diabetes, as we know it, at an increasingly
younger age. When I was first diagnosed, they first thought I was a type 2 diabetic and
they said, “Well that’s strange because it’s usually old, sedentary, obese people.” I was
38 and I was training for a marathon and I just didn’t fit in that. It turned out eventually I
was type 1 but they looked at me as a type 2 at first.
Why is there a low event rate? When I looked at it and I looked at the
So you are looking at, you know, for whom is this cardiovascular risk
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
DR. BURMAN: Ms. Killion.
DR. KILLION: Thank you. I wanted to step back from a patient point of